Altre lingue Navamedic ASA

Azioni

Tempo reale Oslo Bors Altri mercati azionari 14:46:27 03/07/2024			Variaz. 5gg	Var. 1 gen.
33,8 ^NOK	+2,11%		+3,05%	-7,90%

25/06	Orion ottiene la licenza per commercializzare il farmaco di Navamedic contro il morbo di Parkinson in Europa	MT
24/06	Navamedic ASA e Orion Corporation firmano un accordo di licenza e fornitura per Flexilev in Europa	CI

Orion Obtains License to Market Navamedic's Parkinson's Disease Drug in Europe	25/06
Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe	24/06
Navamedic ASA and Orion Corporation Sign License & Supply Agreement for Flexilev in Europe	24/06
Navamedic ASA: Minutes of Annual General Meeting	04/06
Navamedic ASA Receives Confirmation of an Extension of Its Contract with the Norwegian Hospital Procurement Trust for Continued Delivery of Antibodies to Norwegian Hospitals	16/05
Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals	16/05
Navamedic ASA: Notice of Annual General Meeting	14/05
Navamedic Rolls Out Erectile Dysfunction Drug in Sweden	06/05
Navamedic ASA: Broad launch for Eroxon® in Sweden today	06/05
Navamedic ASA: Annual Report 2023	30/04
Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04
Navamedic Q1 2024: Successful product launch and steady operational progress	30/04
Navamedic ASA: Invitation to 2024 1st quarter presentation	23/04
Disclosure in NAVAMEDIC ASA	21/03
Major shareholder disclosure in Navamedic ASA	18/03
Navamedic ASA - Mandatory notification of trade by primary insider	15/03
Navamedic ASA: Resolution to increase the share capital in connection with exercise of employee options	15/03
Navamedic welcomes new shareholders	13/03
Navamedic ASA - Notification of Major Holdings	13/03
Ingerø Reiten Investment Divests Navamedic Stake in NOK95 Million Deal	13/03

Non ci sono risultati per questa ricerca